Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology II1 Apr 2017MP83-10 CORRELATION BETWEEN CABAZITAXEL RESISTANCE AND EMT IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER Hiroshi Hongo, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Akira Miyajima, and Mototsugu Oya Hiroshi HongoHiroshi Hongo More articles by this author , Takeo KosakaTakeo Kosaka More articles by this author , Yota YasumizuYota Yasumizu More articles by this author , Yasumasa MiyazakiYasumasa Miyazaki More articles by this author , Eiji KikuchiEiji Kikuchi More articles by this author , Akira MiyajimaAkira Miyajima More articles by this author , and Mototsugu OyaMototsugu Oya More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2578AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Recently, cabazitaxel (CBZ) was identified as the most effective cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory CRPC. Accumulating evidence suggests EMT induced by androgen-deprivation therapy or docetaxel explains in part the aggressiveness of CRPC. The aim of this study was to screen for EMT inhibitory drugs by bioinformatic analysis and exploring the antitumor effect of CBZ for resistant CRPC. METHODS PC3 and DU145 were used in this study. We incubated the cell lines with gradually increasing concentrations of CBZ to establish CBZ-resistant cell lines. In addition, we performed screening tests for candidate drugs to inhibit EMT of metastatic CRPC. The combined effect of CBZ and a candidate EMT inhibitor for CBZ-resistant cell lines was determined using a cell viability assay. RESULTS We established a CBZ-resistant cell line, PC3-CBZR (Figure). PC3-CBZR cells underwent cell division with 3 nM CBZ. We compared the cytotoxic effect of CBZ on PC3 and PC3-CBZR cells using a cell viability assay. The IC50 of CBZ in PC3 and PC3-CBZR cells were 16.0 nM and 2.5 nM, respectively. Real-time PCR showed up-regulation of ZEB family and Vimentin and down-regulation of E-cadherin expression, suggesting PC3-CBZR cells had elevated metastatic potential. We screened for EMT inhibitors using The Broad institute′s connectivity map (CMAP) analysis, with human whole genome array data and identified a candidate drug, KOH513. The relative cell viabilities treated with 10 μM KOH513 in PC3 and PC3-CBZR cells were 60.0 ± 1.7%, 58.7 ± 0.7%, respectively. KOH513 was suggested to have an antitumor effect on CBZ-resistant prostate cancer. Real time PCR and immune fluorescence assay showed that KOH513 down-regulated ZEB family and Vimentin in PC3-CBZR cells at the protein and mRNA levels. We tested the efficacy of KOH513 in CBZ resistance using a cell viability assay. Single-agent administration of 6 nM CBZ or 3 μM KOH513 did not have an antitumor effect in PC3-CBZ cells. However, when treated with 6 nM CBZ and 3 µM KOH513 in combination, PC3-CBZ cell proliferation was significantly suppressed (relative cell viability 77.0 ± 1.7%). In the same manner, we established CBZ-resistant DU145 cells, DU145-CBZR. DU145-CBZR cells had also had an up-regulated EMT pathway, and cell proliferation was suppressed by EMT inhibitor KOH513. These results suggested that KOH513 had potential for reprogramming CBZ resistant CRPC cell lines into sensitive cell lines. CONCLUSIONS Targeting EMT signaling pathways with KOH513 can overcome CBZ resistance in CRPC. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1109-e1110 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Hiroshi Hongo More articles by this author Takeo Kosaka More articles by this author Yota Yasumizu More articles by this author Yasumasa Miyazaki More articles by this author Eiji Kikuchi More articles by this author Akira Miyajima More articles by this author Mototsugu Oya More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.